Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Chief Commercial Officer | June 22, 2021 | June 24, 2021 |
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | Chief Commercial Officer | July 05, 2024 | July 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date June 22, 2021 · Filed June 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,750 |
Reported balance
After 2021-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-22 · Sale · Disposed 3,625 · Balance 105,750 F1: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
Crinetics Pharmaceuticals, Inc.
Report date July 05, 2024 · Filed July 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,259 |
Ending reported balance
After 2024-07-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-07-05 · Exercise / conversion · Acquired 15,000 · Balance 44,259 Row 2 · 2024-07-05 · Sale · Disposed 15,000 · Balance 29,259 F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.08 per share. The range of sales prices on the transaction date was $43.71 to $44.41 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. |
| Stock option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.73 · Expires 2032-03-10 | Direct | 130,000 |
Reported balance
After 2024-07-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-05 · Exercise / conversion · Disposed 15,000 · Balance 130,000 F3: The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.08 per share. The range of sales prices on the transaction date was $43.71 to $44.41 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3: The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2024 Filed Jul 9, 2024 18:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $19.73 | $0.00 |
DisclosureSEC source: 0000950170-24-082529 · ownership.xml · derivative · entry 3 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 15,000 shares Expires 2032-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 18:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 15,000 | $44.08 | $661,200.00 |
DisclosureSEC source: 0000950170-24-082529 · ownership.xml · nonDerivative · entry 2 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,259 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.08 per share. The range of sales prices on the transaction date was $43.71 to $44.41 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 18:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 15,000 | $19.73 | $295,950.00 |
DisclosureSEC source: 0000950170-24-082529 · ownership.xml · nonDerivative · entry 1 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 17:08 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $19.73 | $0.00 |
DisclosureSEC source: 0000950170-24-076871 · ownership.xml · derivative · entry 3 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 15,000 shares Expires 2032-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 17:08 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 15,000 | $44.66 | $669,900.00 |
DisclosureSEC source: 0000950170-24-076871 · ownership.xml · nonDerivative · entry 2 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,259 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.66 per share. The range of sales prices on the transaction date was $43.96 to $45.11 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 17:08 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 15,000 | $19.73 | $295,950.00 |
DisclosureSEC source: 0000950170-24-076871 · ownership.xml · nonDerivative · entry 1 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:34 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Tax withholdingCommon Stock | 1,741 | $38.14 | $66,401.74 |
DisclosureSEC source: 0001209191-24-005011 · doc4.xml · nonDerivative · entry 1 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,259 F1 · kind: Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 1, 2023. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:18 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 63,000 | $0.00 Strike: $43.51 | $0.00 |
DisclosureSEC source: 0001209191-24-004612 · doc4.xml · derivative · entry 2 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2034-03-03 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:18 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004612 · doc4.xml · nonDerivative · entry 1 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:47 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 65,250 | $0.00 Strike: $19.64 | $0.00 |
DisclosureSEC source: 0001209191-23-015619 · doc4.xml · derivative · entry 2 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,250 Underlying: Common Stock · 65,250 shares Expires 2033-02-28 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:47 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015619 · doc4.xml · nonDerivative · entry 1 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024. Read SEC document |
| March 10, 2022 Filed Mar 10, 2022 16:51 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $19.73 | $0.00 |
DisclosureSEC source: 0001209191-22-017938 · doc4.xml · derivative · entry 1 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 22:44 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,625 | $89.22 | $323,422.50 |
DisclosureSEC source: 0001209191-21-043137 · doc4.xml · nonDerivative · entry 1 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,750 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 23:05 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 15,625 | $75.00 | $1,171,875.00 |
DisclosureSEC source: 0001209191-21-002801 · doc4.xml · nonDerivative · entry 1 Hassard James · CIK 0001799357 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,375 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.